ong-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
Phase 3
- Conditions
- Pulmonary Arterial Hypertension
- Registration Number
- JPRN-jRCT2080221333
- Lead Sponsor
- Pfizer Japan Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Subject who completed the B1321052 study as planned
Exclusion Criteria
1.Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mm Hg or sitting diastolic blood pressure >100 mm Hg at Screening
2.Has hypotension defined as systolic arterial pressure <90 mm Hg after sitting for 5 minutes at Screening.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method